{"id":"travoprost-latanoprost-or-bimatoprost","safety":{"commonSideEffects":[{"rate":"10–50","effect":"Increased iris pigmentation"},{"rate":"25–50","effect":"Conjunctival hyperemia"},{"rate":"5–15","effect":"Eyelash growth (hypertrichosis)"},{"rate":"5–20","effect":"Eye irritation or discomfort"},{"rate":"5–15","effect":"Periocular skin darkening"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Travoprost, latanoprost, and bimatoprost are all prostaglandin analogs that bind to the FP prostaglandin receptor on the ciliary muscle and trabecular meshwork. By activating this receptor, they enhance drainage of aqueous humor through the uveoscleral (unconventional) pathway, leading to decreased intraocular pressure. This mechanism makes them effective for treating glaucoma and ocular hypertension.","oneSentence":"These prostaglandin F (FP) receptor agonists increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:14:03.301Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT07074782","phase":"","title":"Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues","status":"NOT_YET_RECRUITING","sponsor":"Association for Innovation and Biomedical Research on Light and Image","startDate":"2026-01","conditions":"Glaucoma","enrollment":1500},{"nctId":"NCT02390284","phase":"PHASE3","title":"Stop Retinal Ganglion Cell Dysfunction Study","status":"TERMINATED","sponsor":"University of Miami","startDate":"2015-09","conditions":"Glaucoma","enrollment":28},{"nctId":"NCT04828057","phase":"","title":"Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting","status":"COMPLETED","sponsor":"Santen Pharmaceutical (Taiwan) Co., LTD","startDate":"2021-09-01","conditions":"Ocular Surface Disease, Primary Open Angle Glaucoma","enrollment":50},{"nctId":"NCT05241938","phase":"NA","title":"PSLT Compared to Prostaglandin Analogue Eye Drops","status":"UNKNOWN","sponsor":"Federal University of Rio Grande do Sul","startDate":"2021-09-01","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":75},{"nctId":"NCT01927406","phase":"PHASE4","title":"The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2014-06","conditions":"Thyroid Eye Disease, Ocular Hypertension, Glaucoma","enrollment":""},{"nctId":"NCT01535768","phase":"PHASE4","title":"Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves","status":"UNKNOWN","sponsor":"Credit Valley EyeCare","startDate":"2012-02","conditions":"Glaucoma","enrollment":150},{"nctId":"NCT01263444","phase":"PHASE4","title":"Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-03","conditions":"Glaucoma, Ocular Hypertension","enrollment":47},{"nctId":"NCT01493427","phase":"PHASE4","title":"Efficacy of Changing to TRAVATAN® From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-12","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":202},{"nctId":"NCT01253902","phase":"PHASE4","title":"Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-12","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":164},{"nctId":"NCT01361841","phase":"NA","title":"Effects of Latanoprost, Bimatoprost and Travoprost in Patients With Latanoprost-resistant Glaucoma","status":"UNKNOWN","sponsor":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","startDate":"2009-01","conditions":"Ocular Hypertension, Primary Glaucoma","enrollment":141},{"nctId":"NCT00329095","phase":"PHASE4","title":"An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance","status":"COMPLETED","sponsor":"Robin, Alan L., M.D.","startDate":"2005-12","conditions":"Glaucoma, Ocular Hypertension","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"travoprost, latanoprost, or bimatoprost","genericName":"travoprost, latanoprost, or bimatoprost","companyName":"Robin, Alan L., M.D.","companyId":"robin-alan-l-m-d","modality":"Small molecule","firstApprovalDate":"","aiSummary":"These prostaglandin F (FP) receptor agonists increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}